‘We need to see the data’: FDA’s Xeljanz safety warning stirs concerns for JAK inhibitors

For Pfizer and its JAK inhibitor, Xeljanz, February rang in with the sound of alarm bells, as the FDA issued its third warning about the drug in 2 years.In this latest alert regarding tofacitinib, the FDA warned providers of an increased risk for serious heart-related issues and cancer among older patients, compared with TNF inhibitors.However, unlike prior FDA warnings about the JAK inhibitor, which were limited to the higher 10 mg dosage only approved for ulcerative colitis, this newest announcement raises red flags for both the 10 mg and 5 mg doses, casting a shadow over all three of the drug’sRead More

Share on facebook
Share on twitter
Share on linkedin